The Interplay between Mutagenesis and Extrachromosomal DNA Shapes Urothelial Cancer Evolution
Duy Nguyen(Harvard University), Bishoy M. Faltas(Cornell University), Jenna E. Moyer(Cornell University), Scott T. Tagawa(Cornell University), Ana M. Molina(Cornell University), Jyothi Manohar(Cornell University), William F. Hooper(New York Genome Center), Heather Geiger(New York Genome Center), Jones T. Nauseef(Cornell University), Nicolas Robine(New York Genome Center), Michael Sigouros(Cornell University), David M. Nanus(Cornell University), Jennifer Shelton(Kansas State University), Timothy R. Chu(New York Genome Center), Juan Miguel Mosquera(NewYork–Presbyterian Hospital), Andrea Sboner(NewYork–Presbyterian Hospital), Douglas S. Scherr(NewYork–Presbyterian Hospital), Olivier Elemento, Zoe R. Goldstein(New York Genome Center), Weisi Liu(Cornell University), David Wilkes(Cornell University), Rahul Singh(Cornell University), Giorgio Inghirami(Cornell University), Lara Winterkorn(New York Genome Center), Minita Shah(New York Genome Center), Cora N. Sternberg(Radboud University Nijmegen)
Cited by 2
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial
|The Lancet|2002|1.7k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k